A renowned medicine biotechnology company, Molecular Stethoscope, Inc., introduced a publication on human proof-of-concept study for Alzheimer’s Disease through its proprietary cell-free messenger RNA (cf-mRNA)- Artificial Intelligence Technology Platform.

The study appeared in the American Association’s December 2020 issue for the Advancement of Science journal, Science Advances. “The Technology Platform’s dynamic detection and monitoring of dysregulated genes and biological processes in Alzheimer’s Disease provides a promising new approach to stratify patients and to follow disease course and targeted intervention,” commented James Brewer, M.D., Ph.D., Director of the Shiley-Marcos Alzheimer’s Disease Research Center and Chair of the Department of Neuroscience at the University of California in San Diego. Dr. Brewer is a collaborator in the study.

The study shows in-depth data to direct the development of novel, non-invasive blood-based products for Alzheimer’s Disease prognosis and diagnosis, with expected initial impact in stratifying patients that accelerate drug discovery and development studies. Further studies will help in knowing the advancement in products for patient management and clinical practice.

“Our proprietary Technology Platform not only can be used for Alzheimer’s Disease but may have value for other neurodegenerative diseases such as Multiple Sclerosis where the non-invasive monitoring of disease progression and response to therapies are critical to improve the health of patients,” commented Guillermo Elias, Ph.D., Chief Executive Officer of Molecular Stethoscope.

The three significant challenges faced by Alzheimer’s Disease diagnosis and prognosis include the complexity of underlying pathophysiology, the disease’s heterogeneity, and lack of non-invasive brain function tools.

“Our genome-wide cell-free transcriptome study highlights the rigorous and reproducible analytical performance of our Technology Platform by using reference material from the Extracellular RNA Consensus Consortium combined with custom RNA library preparation and pioneering data analysis,” said John J. Sninsky, Ph.D., Chief Scientific Officer at Molecular Stethoscope.